Gastroenterology
Peginterferon alfa-2b
PBAC's latest decision on Peginterferon alfa-2b: Recommended with restriction (2005). Considered for treatment of chronic hepatitis C in patients who have not previously received interferon treatment, with or without ribavirin.
PBAC outcome
Recommended with restriction
2005
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
2005 → 2005
Eligible population patients with no or mild hepatitis C
Therapy area Gastroenterology Line of therapy First-line Evidence base RCT Primary endpoint SVR Key trials C/I98-580, Mangia (2004), Verbaan (2002), Wright (2005a) Comparator Pegatron therapy in patients with stage F1/A2-A3, F2, F3 and F4 fibrosis Economic model CUA Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.